Sun Pharma inks global licensing agreement to commercialise Philogen’s anti-cancer immunotherapy

As per the terms of the agreement, Sun Pharma will have the exclusive worldwide rights for commercialising Fibromun.

Leave a Reply

Your email address will not be published. Required fields are marked *